The Efficacy of Bevacizumab, Sorafenib, and Retinoic Acid on Rat Endometriosis Model

Basit Öğe Kaydı
dc.contributor.authorOzer, Hatice
dc.contributor.authorBoztosun, Abdullah
dc.contributor.authorAcmaz, Gokhan
dc.contributor.authorAtilgan, Remzi
dc.contributor.authorAkkar, Ozlem Bozoklu
dc.contributor.authorKosar, Mehmet Ilkay
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T10:03:14Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T10:03:14Z
dc.date.issued2013
dc.department[Acmaz, Gokhan] Kayseri Training & Educ Hosp Med, Dept Obstet & Gynecol, Kayseri, Turkey -- [Ozer, Hatice] Cumhuriyet Univ, Sch Med, Dept Pathol, Sivas, Turkey -- [Boztosun, Abdullah -- Akkar, Ozlem Bozoklu] Cumhuriyet Univ, Sch Med, Dept Obstet & Gynecol, Sivas, Turkey -- [Atilgan, Remzi] Firat Univ, Sch Med, Dept Obstet & Gynecol, TR-23169 Elazig, Turkey -- [Kosar, Mehmet Ilkay] Cumhuriyet Univ, Sch Med, Dept Anat, Sivas, Turkeyen_US
dc.description.abstractBlood vessels are necessary for development and maintenance of the endometriosis and blood flow supplies oxygen and essential nutrient to the disease. Local angiogenesis is regulated by vascular endothelial growth factor (VEGF) and inhibitors of VEGF may be a novel therapeutic approach. We inducted endometriosis in 43 rats and they were randomly allocated into 4 groups. The rats in group I (control n = 11) were given no medication. The rats in group II (n = 11) were given bevacizumab. The rats in group III (n = 11) were given Sorafenib, and the rats in group IV (n = 10) were given retinoic acid (RA). Then groups were compared for microvessel density, VEGF, soluble tyrosine-kinase receptor, ovarian reserve, and treatment effectivity. All these medications were effective on endometriosis and we detected that volume of endometriotic implants were significantly decreased. Ovarian reserve was not affected from the medication, in addition RA have induced reproductive capacity.en_US
dc.description.sponsorshipCumhuriyet Universityen_US
dc.description.sponsorshipThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Cumhuriyet University financially supported this study.en_US
dc.identifier.doi10.1177/1933719112452941en_US
dc.identifier.endpage32en_US
dc.identifier.issn1933-7191
dc.identifier.issn1933-7205
dc.identifier.issue1en_US
dc.identifier.pmid22895024en_US
dc.identifier.scopus2-s2.0-84870542388en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage26en_US
dc.identifier.urihttps://dx.doi.org/10.1177/1933719112452941
dc.identifier.urihttps://hdl.handle.net/20.500.12418/8930
dc.identifier.volume20en_US
dc.identifier.wosWOS:000311803000003en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSAGE PUBLICATIONS INCen_US
dc.relation.ispartofREPRODUCTIVE SCIENCESen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectendometriosisen_US
dc.subjectraten_US
dc.subjecttreatmenten_US
dc.titleThe Efficacy of Bevacizumab, Sorafenib, and Retinoic Acid on Rat Endometriosis Modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu